Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in VKTX — Viking Therapeutics, Inc.

CIK 1423053 MIAMI, FL
Back to VKTX Full portfolio

Position in VKTX

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$41,072,670
-$19,873,900 QoQ
Shares Held
1,262,221
-27.1% QoQ
Ownership
1.09%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in VKTX Over Time

Shares Held

Position Value (USD)

Derivatives in VKTX

reported options exposure · as of Mar 31, 2026
CallValue
$30,086,484
CallShares
924,600
PutValue
$13,936,882
PutShares
428,300

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

CITADEL ADVISORS LLC holds $5,784,241,435 across 374 Biotechnology names. VKTX ranks #33 (0.7% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 INSM
INSMED Inc
 2,182,571 $356,894,009
2 ONC
BeOne Medicines Ltd.
 1,032,298 $306,561,536
3 BMRN
Biomarin Pharmaceutical Inc
 4,512,634 $254,918,694
4 JAZZ
Jazz Pharmaceuticals plc
 1,259,444 $238,097,887
5 MDGL
Madrigal Pharmaceuticals, Inc.
 453,843 $237,573,195
6 BBIO
BridgeBio Pharma, Inc.
 3,173,940 $235,696,783
7 TERN
Terns Pharmaceuticals, Inc.
 3,218,810 $169,695,662
8 PTGX
Protagonist Therapeutics, Inc
 1,551,900 $163,570,260

All Filings in VKTX

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $41,072,670 1,262,221
2026-03-31 $13,936,882 428,300
2026-03-31 $30,086,484 924,600
2025-12-31 $50,504,408 1,435,600
2025-12-31 $60,946,570 1,732,421
2025-12-31 $32,914,408 935,600
2025-09-30 $49,888,427 1,898,342
2025-09-30 $33,317,784 1,267,800
2025-09-30 $32,392,728 1,232,600
2025-06-30 $29,078,450 1,097,300
2025-06-30 $20,950,900 790,600
2025-06-30 $23,133,837 872,975
2025-03-31 $31,868,340 1,319,600
2025-03-31 $39,873,823 1,651,090
2025-03-31 $20,346,375 842,500
2024-12-31 $51,768,760 1,286,500
2024-12-31 $59,759,578 1,485,079
2024-12-31 $25,371,320 630,500
2024-09-30 $67,456,805 1,065,500
2024-09-30 $81,866,161 1,293,100
2024-09-30 $93,235,117 1,472,676
2024-06-30 $51,599,934 973,400
2024-06-30 $34,615,530 653,000
2024-06-30 $24,727,998 466,478
2024-03-31 $73,943,418 901,749
2024-03-31 $106,550,800 1,299,400
2024-03-31 $75,235,000 917,500
2023-12-31 $5,151,248 276,800
2023-12-31 $4,337,991 233,100
2023-12-31 $1,331,861 71,567
2023-09-30 $3,944,241 356,300
2023-09-30 $2,231,712 201,600
2023-06-30 $1,454,311 89,717
2023-06-30 $5,642,701 348,100
2023-06-30 $9,831,365 606,500
2023-03-31 $2,484,046 149,192
2023-03-31 $9,780,210 587,400
2023-03-31 $5,039,955 302,700
2022-12-31 $225,186 23,956
2022-12-31 $1,487,080 158,200
2022-12-31 $4,341,860 461,900
2022-09-30 $122,672 45,100
2022-09-30 $142,110 52,247
2022-09-30 $189,856 69,800
2022-06-30 $206,346 71,400
2022-06-30 $346,365 119,850
2022-06-30 $130,050 45,000
2022-03-31 $1,834,935 611,645
2022-03-31 $185,400 61,800
2022-03-31 $253,200 84,400

Report a Problem

Category
Description
Email (optional, for follow-up)